HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Crawford closer to confirmation

This article was originally published in The Rose Sheet

Executive Summary

Acting Commissioner Lester Crawford's nomination to fill the post permanently clears Senate Health Committee by a voice vote June 15. Full Senate vote will be delayed, however, since Sens. Patty Murray (D-Wash.) and Hillary Clinton (D-N.Y.) have placed a hold on the nomination pending a decision by FDA on over-the-counter switch application for Barr's Plan B emergency contraceptive. Sen. Tom Coburn (R-Okla.) has also placed a hold on Crawford's confirmation due to concerns about FDA's relabeling of condoms. Crawford was cleared of certain allegations regarding inappropriate behavior with a subordinate by a June 7 HHS Inspector General report, enabling Health panel vote (1"The Rose Sheet" June 6, 2005, p. 10)...

You may also be interested in...



IG Inquiry Clears Crawford Of Three Personal Conduct Allegations

The conclusion of the HHS Inspector General's investigation into allegations against FDA Commissioner-nominee Lester Crawford could remove one roadblock in his confirmation process

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS013132

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel